Cost-effectiveness analysis of screening for neonatal alloimmune thrombocytopenia was based on invalid assumption [5]

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 115, Issue 3, 2008, Pages 412-413

  Fretheim, A ^a  

^a NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; HUMAN; LETTER; NEWBORN ALLOIMMUNE THROMBOCYTOPENIA; NEWBORN SCREENING; PEER REVIEW; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; THROMBOCYTOPENIA;

COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 38049042305     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2007.01615.x     Document Type: Letter

References (2)

1. Killie MK, Kjeldsen-Kragh J, Husebekk A, Skogen B, Olsen JA, Kristiansen IS. Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia. BJOG 2007 114 : 588 95.
2. Kjeldsen-Kragh J, Killie MK, Tomter G, Golebiowska E, Randen I, Hauge R, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007 110 : 833 9.